Ideaya Biosciences (IDYA)
NASDAQ:IDYA
Want to see IDYA full AI Analyst Report?
Top Page
IDEAYA Biosciences
(NASDAQ:IDYA)
Select Model
Select Model
Rating:55Neutral
Price Target:
$29.00
▼(-14.48% Downside)
Action:Reiterated
Date:06/11/26
The score is anchored by mixed fundamentals: a strong, low-leverage balance sheet and improving revenue are offset by sizable ongoing losses and negative cash flow. Technicals are weak with the stock trading below key moving averages and negative MACD, while valuation is constrained by a negative P/E and no dividend. Offsetting these, recent corporate events are notably positive, including compelling clinical/regulatory progress and added capital and partnerships.
Positive Factors
Strong balance sheet / low leverage
Very low leverage and ~ $1.03B in assets give IDEAYA durable financial flexibility to fund R&D and sponsor mid-stage trials without immediate refinancing risk. This reduces solvency pressure during clinical readouts and supports strategic partnerships and program advancement over months.
Negative Factors
Persistent negative cash flow
Although burn has improved significantly, ongoing negative operating and free cash flow requires sustained financing or meaningful operating improvements. Continued negative cash generation constrains optionality and may force program prioritization or further capital raises over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet / low leverage
Very low leverage and ~ $1.03B in assets give IDEAYA durable financial flexibility to fund R&D and sponsor mid-stage trials without immediate refinancing risk. This reduces solvency pressure during clinical readouts and supports strategic partnerships and program advancement over months.
Read all positive factors
IDEAYA Biosciences (IDYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.76B
Dividend YieldN/A
Average Volume (3M)1.01M
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue Growth3118.14%
EPS Growth55.95%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.58
Shares Outstanding95,083,145
10 Day Avg. Volume1,464,912
30 Day Avg. Volume1,012,235
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)2.99
Price to Sales (P/S)13.99
P/FCF Ratio-41.64
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue10.92
Enterprise Value/Gross Profit36.77
Enterprise Value/Ebitda-18.16
Forecast
1Y Price Target
$54.00Price Target Upside59.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-4.34
Revenue Forecast (FY)$34.69M
IDEAYA Biosciences Business Overview & Revenue Model
Company Description
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient grou...
How the Company Makes Money
null...
IDEAYA Biosciences Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
43
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 225.27M | 218.71M | 7.00M | 23.39M | 50.93M | 27.94M |
| Gross Profit | 66.91M | 214.12M | 3.17M | 19.38M | 48.83M | 26.22M |
| EBITDA | -135.46M | -109.11M | -270.64M | -108.95M | -56.55M | -48.04M |
| Net Income | -140.06M | -113.70M | -274.48M | -112.96M | -58.66M | -49.76M |
Balance Sheet | ||||||
| Total Assets | 1.03B | 1.11B | 1.12B | 649.32M | 387.97M | 381.35M |
| Cash, Cash Equivalents and Short-Term Investments | 671.20M | 639.39M | 676.32M | 525.11M | 364.83M | 246.77M |
| Total Debt | 28.60M | 27.91M | 19.17M | 2.87M | 3.48M | 5.18M |
| Total Liabilities | 93.08M | 86.39M | 64.94M | 28.23M | 38.51M | 79.83M |
| Stockholders Equity | 937.27M | 1.02B | 1.06B | 621.09M | 349.45M | 301.51M |
Cash Flow | ||||||
| Free Cash Flow | -87.93M | -73.47M | -251.44M | -117.59M | -90.62M | -58.42M |
| Operating Cash Flow | -85.93M | -71.10M | -247.58M | -115.22M | -87.17M | -55.78M |
| Investing Cash Flow | 109.11M | 69.98M | -502.56M | -158.46M | -33.40M | -69.67M |
| Financing Cash Flow | 4.82M | 29.78M | 677.55M | 362.72M | 97.17M | 145.45M |
IDEAYA Biosciences Technical Analysis
Positive
33.91
Price Trends
29.75
Positive
31.30
Negative
31.13
Negative
Market Momentum
-0.11
Negative
54.57
Neutral
49.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 33.91 is above the 20-day moving average (MA) of 29.01, above the 50-day MA of 29.75, and above the 200-day MA of 31.13, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 54.57 is Neutral, neither overbought nor oversold. The STOCH value of 49.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.
IDEAYA Biosciences Risk Analysis
IDEAYA Biosciences disclosed 76 risk factors in its most recent earnings report. IDEAYA Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IDEAYA Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.05B | ― | -1.41% | ― | 95.29% | 98.21% | |
65 Neutral | $4.84B | ― | -26.79% | ― | 96.03% | 82.27% | |
55 Neutral | $2.76B | -19.14 | -13.96% | ― | 3118.14% | 55.95% | |
55 Neutral | $4.32B | -24.92 | -244.61% | ― | ― | -28.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.75B | -4.43 | -34.11% | ― | 78.34% | -161.91% | |
48 Neutral | $2.99B | -49.41 | -5.89% | ― | 157.97% | 86.11% |
* Healthcare Sector Average
IDYA
IDEAYA Biosciences
30.23
7.84
35.02%
AGIO
Agios Pharma
31.82
-3.93
-10.99%
TVTX
Travere Therapeutics
53.80
39.12
266.49%
CELC
Celcuity
88.24
75.78
608.19%
ARQT
Arcutis Biotherapeutics
25.58
12.18
90.90%
BEAM
Beam Therapeutics
31.12
14.50
87.24%
IDEAYA Biosciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
IDEAYA Biosciences Raises $324 Million in Equity Offering
Positive
Jun 10, 2026
On June 8, 2026, IDEAYA Biosciences entered into an underwriting agreement with a syndicate of investment banks to sell 5,555,556 shares of common stock and pre-funded warrants for 5,555,576 additional shares, with public pricing set at $27.00 per...
Business Operations and StrategyProduct-Related Announcements
IDEAYA, Roche launch PRMT5 and pan-RAS collaboration
Positive
Jun 3, 2026
On June 3, 2026, IDEAYA Biosciences announced a clinical collaboration with Roche to test IDEAYA’s investigational PRMT5 inhibitor IDE892 with Roche’s pan-RAS inhibitor RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
IDEAYA Highlights Positive Phase 2/3 Darovasertib Trial Results
Positive
Jun 1, 2026
On June 1, 2026, IDEAYA Biosciences and Servier presented complete primary analysis data from the global Phase 2/3 registrational OptimUM-02 trial of darovasertib plus crizotinib in first-line HLA*A2:01 negative metastatic uveal melanoma at the AS...
Private Placements and FinancingRegulatory Filings and Compliance
IDEAYA Biosciences Files New Shelf Registration Statement
Neutral
May 5, 2026
On May 5, 2026, IDEAYA Biosciences filed a new automatic shelf registration statement on Form S-3ASR with the SEC to replace its prior shelf registration that was set to expire on June 26, 2026, effectively terminating the older registration under...
Business Operations and StrategyProduct-Related Announcements
IDEAYA, AstraZeneca launch global IDE849-Imfinzi lung cancer trial
Positive
Apr 9, 2026
On April 8, 2026, IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDE849, its investigational DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca’s PD-L1 inhibitor Imfinzi in extensive-stage small ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.